Pharmacoeconomic Analysis Methods Should Be Standardized - JAMA
Executive Summary
Standardized methods of pharmacoeconomic analysis should be developed to better enable study comparisons, Sheldon Krimsky, PhD, Tufts University, advocated in an Oct. 20 Journal of the American Medical Association editorial.
You may also be interested in...
Voluntary Financial Disclosure Guidelines Being Considered By PhRMA
PhRMA is considering the development of voluntary guidelines on financial interest disclosure for researchers publishing study results as part of a strategy to improve the pharmaceutical industry's image in a climate in which questions have arisen about investigator-sponsor relationships.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011